Skip to content
Palanor is in early release, with our founding customers.Become a founding customer →
The Real Rate Index45.30.00Palanor: Inflation Pulse50.7+0.09Palanor: Geopolitical Stress60.0-2.16Palanor: Liquidity57.9-0.79Palanor: Capital Tightness47.5+0.91Palanor: Industrial Pulse70.10.00Palanor: AI Margin Compression53.4+0.29Palanor: Consumer Confidence48.6+0.50Palanor: US Dollar Strength46.50.00Palanor: Labor Heat63.2-0.01Palanor: Recession Vocabulary28.1+0.54Palanor: Uncertainty Index53.4+1.24Palanor: US Jobs Health40.30.00Palanor: Energy Transition37.0-0.52Palanor: Reshoring Sentiment22.8+0.54Palanor: AI Substitution28.4-0.24The Social Fabric Index45.70.00Palanor: Geopolitical Anxiety19.4-0.45Palanor: Quit Pressure37.6+0.42The Mania Index88.00.00The Palanor Index57.1-0.51Cost Disease Spread33.20.00Palanor: US vs China49.5-0.17Rise of Socialism Index40.8-0.26The Bubble Memory79.90.00Palanor: Steward Confidence50.8+0.13The Long Watch90.30.00The Reshoring Index55.2+0.00The Capital Return Index81.0-0.75The Discourse Index72.4+1.83The Hesitation Index30.8-6.58Palanor AI Inference Cost Index71.2-0.03The AI Capex Race Index78.4+1.36The Boardroom Index82.5-0.00The Layoff Cycle Index32.8-2.51Capital Deployment Posture Index62.3+1.26The Consumer Health Index41.7-2.96Labor Hours Composite44.40.00The Dollar Erosion Index66.6+0.14Palanor: Risk Appetite36.2+0.83
PalanorPalanor

Company Dossier · Health Care

Eli Lilly and Company

LLYNYSEPharmaIndianapolis, US-IN, USMega capWebsite ↗
  • S&P 500
  • S&P 100
  • Russell 1000

What Eli Lilly and Company is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.

Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →

The latest read

Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.

  • Revenue over the four quarters to June 30, 2026: $79.7 billion, up 50% from a year earlier.SEC EDGAR filings (XBRL)
  • Share buybacks in the fiscal year to December 31, 2025: $4.11 billion.SEC EDGAR filings (10-K)
  • Long-term debt issued in the fiscal year to December 31, 2025: $13.2 billion.SEC EDGAR filings (10-K)
  • Latest earnings call or results release (August 5, 2026): sentiment 0.80 on a −1 to +1 scale (confident, opportunity-framed), confidence 0.90 of 1.Palanor Discourse
  • Guidance in the last 90 days: 1 outlook figure raised, 0 lowered, 1 held.Guidance Ledger (8-K results releases)
  • Latest annual report (filed February 12, 2026): 0 risk factors added, 0 removed.Risk Factor Changes (10-K Item 1A)
  • Insiders were net sellers in Q3 2026: $16.0 million on the open market.SEC Form 4
  • 4,652 institutional managers reported a position at June 30, 2026 (+260 on the quarter before).SEC Form 13F
  • H-1B filings certified in Q2 2026: 135 (322 a year earlier).U.S. Department of Labor (OFLC)
  • Headlines in the last 30 days: 19, of which 2 read positive and 0 negative.Palanor headline tone

Risk events (12 months): 1 — latest OSHA inspection, Apr 20, 2026 →

Company Posture

How Company Posture is measured →

What Eli Lilly and Company is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.

Expanding ↔ Retrenching

Withheld: 50% of the evidence is readable at this date (needs 60%).

Confident ↔ Hedging

Confident

HedgingConfident

Pressure

Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).

Credit

How these are built →

Eli Lilly and Company's borrowing from its SEC filings: the bonds it priced and the debt on its latest balance sheet. A description, not a rating.

Debt on the balance sheet

$54.9B

  • Due within a year $7.0B
  • Longer term $47.9B
  • Default point $31.0B (short + ½ long)

Finance leases included · Jun 30, 2026 filing

Bonds priced, last 12 months

$9.0B

U.S. dollar tranches with a term sheet on EDGAR. Deals sold under Rule 144A file none and are not counted.

PricedAmountCouponMaturesSpreadYield
May 6, 2026$500MSOFR + 46bp2029 (3y)——
May 6, 2026$1.25B4.650%2033 (7y)+48bp4.653%
May 6, 2026$1.5B4.375%2031 (5y)+40bp4.399%
May 6, 2026$750M4.150%2029 (3y)+28bp4.171%
May 6, 2026$1.5B4.850%2036 (10y)+55bp4.896%
May 6, 2026$1B5.700%2066 (40y)+80bp5.739%
May 6, 2026$1.75B5.600%2056 (30y)+68bp5.619%
May 6, 2026$750MSOFR + 35bp2028 (2y)——
Aug 18, 2025$1.25B4.900%2035 (10y)+57bp4.909%
Aug 18, 2025$1B4.000%2028 (3y)+28bp4.014%
Aug 18, 2025$750M4.250%2031 (6y)+40bp4.255%
Aug 18, 2025$750MSOFR + 53bp2028 (3y)——

From the pricing term sheets Eli Lilly and Company filed with the SEC. Spread is to the benchmark Treasury (or Bund, Gilt) at pricing.

Charts

Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.

Cash flow

Business

Eli Lilly and Company: operating cash flow and capital expenditure

Trailing twelve months, $ billions, from SEC filings

Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Eli Lilly and Company: revenue, trailing twelve months

$ billions, from SEC filings

$79.7BData to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

Capital returned and raised

Business

Eli Lilly and Company: share buybacks by fiscal year

Cash paid to repurchase common stock, $ billions, from the 10-K

$4.1BData to Dec 2025
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Eli Lilly and Company: debt issued and repaid by fiscal year

Long-term debt, $ billions, from the 10-K

Data to Dec 2025
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Eli Lilly and Company: debt due within a year and cash

At each balance-sheet date, $ billions, from SEC filings

Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Eli Lilly and Company: interest coverage

Operating income ÷ interest expense, trailing twelve months, from SEC filings

29.8Data to Dec 2025
ImageDataU.S. Securities and Exchange Commission, EDGAR

What the company says

Business

Eli Lilly and Company: guidance raised minus lowered

Guidance Ledger statements by quarter

1.0Data 23 days ago
ImageDataGuidance Ledger by Palanor · source: SEC EDGAR
Business

Eli Lilly and Company: earnings call sentiment

Palanor Discourse score per call, −1 to +1

0.80Data to Aug 2026
ImageDataPalanor calculation
Business

Eli Lilly and Company: earnings call confidence

Palanor Discourse score per call, 0 to 1

0.90Data to Aug 2026
ImageDataPalanor calculation
Business

Eli Lilly and Company: risk factors added per annual report

New Item 1A risk factors in each 10-K

0.0Data to Feb 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

Hiring and ownership

Business

Eli Lilly and Company: H-1B filings certified

Labor Condition Applications by quarter received

135.0Data to Jun 2026
ImageDataU.S. Department of Labor, Office of Foreign Labor Certification disclosure data, dol.gov
Business

Eli Lilly and Company: insider net buying

Open-market purchases minus sales by officers and directors, $ millions, by quarter

−$16MData 23 days ago
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Eli Lilly and Company: institutional holders

Managers reporting a position on Form 13F, by quarter

4,652Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

News

Business

Eli Lilly and Company: headline tone

Net share of positive headlines, trailing 28 days, −1 to +1

0.15Data 6 days ago
ImagePalanor calculation from news headlines (tone words only)

In the news

Headlines that name Eli Lilly and Company, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.

30 days
19 headlines
11% positive · 0% negative
90 days
23 headlines
13% positive · 0% negative

Filings and records

The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.

  1. Oct 21, 2026Lobbying
    Lobbying report (VENN STRATEGIES)third_quarter 2026 · $0.1 million
  2. Oct 20, 2026Lobbying
    Lobbying report (TODD STRATEGY GROUP)third_quarter 2026 · $0.1 million
  3. Oct 20, 2026Lobbying
    Lobbying report (MARSHALL & POPP, LLC)third_quarter 2026 · $0.1 million
  4. Oct 20, 2026Lobbying
    Lobbying report (WILLIAMS AND JENSEN, PLLC)third_quarter 2026 · $0.1 million
  5. Oct 20, 2026Lobbying
    Lobbying report (TARPLIN, DOWNS & YOUNG, LLC)third_quarter 2026 · $0.1 million
  6. Oct 20, 2026Lobbying
    Lobbying report (MONUMENT ADVOCACY)third_quarter 2026 · $0.0 million
  7. Oct 20, 2026Lobbying
    Lobbying report (TIBER CREEK HEALTH STRATEGIES, INC.)third_quarter 2026 · $0.1 million
  8. Oct 20, 2026Patent
    Patent granted: LAG-3 AND PD-1/LAG-3-ANTIBODIESUS 12767714
  9. Oct 20, 2026Patent
    Patent granted: PHYSIOLOGICAL DATA MONITORING SYSTEMUS 12770737
  10. Oct 19, 2026Lobbying
    Lobbying report (FEROX STRATEGIES)third_quarter 2026 · $0.1 million
  11. Oct 14, 2026Trademark
    Trademark application: VERYRETAH
  12. Oct 14, 2026Trademark
    Trademark application: RETAKYNEK
  13. Oct 9, 2026Trademark
    Trademark application: RETAZURA
  14. Oct 9, 2026Trademark
    Trademark application: LUMORETA
  15. Oct 9, 2026Trademark
    Trademark application: ADMIRETA
  16. Sep 22, 2026Patent
    Patent granted: Incretin Analogs and Uses ThereofUS 12741999
  17. Sep 15, 2026Patent
    Patent granted: MACROCYCLIC GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTSUS 12735433
  18. Sep 8, 2026Patent
    Patent granted: MrgprX2 Antagonists for the Treatment of Inflammatory DisordersUS 12728117
  19. Jun 30, 2026Private credit
    Loans held by business development companies (Eli Lilly & Co.)$1.0 million at cost
  20. May 7, 20268-K
    Shareholder vote resultsItem 5.07
  21. Apr 20, 2026Risk event
    OSHA complaint inspection: ELI LILLY & COOSHA
  22. Feb 12, 202610-K
    Annual report (10-K)0 risk factors added, 0 removed
  23. Nov 21, 20258-K
    Director or officer changeItem 5.02
  24. Sep 17, 2025Risk event
    OSHA complaint inspection: ELI LILLY & COMPANYOSHA
  25. May 8, 20258-K
    Shareholder vote resultsItem 5.07
  26. Feb 19, 202510-K
    Annual report (10-K)0 risk factors added, 0 removed
  27. Nov 19, 20248-K
    Director or officer changeItem 5.02
  28. Feb 21, 202410-K
    Annual report (10-K)1 risk factors added, 1 removed

Peers

Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.

CompanyRevenueFree cash flowThrough
Merck & Co. MRK$66.6B$16.1BJun 30, 2026
Johnson & Johnson JNJ$97.9B$22.2BJun 28, 2026
Pfizer Inc. PFE$63.7B$11.0BJun 28, 2026
HCA Healthcare HCA$76.4B$7.9BMar 31, 2026
AbbVie Inc. ABBV$64.4B$18.2BJun 30, 2026
Bristol Myers Squibb BMY$49.2B$11.4BJun 30, 2026
Thermo Fisher Scientific TMO$46.3B$7.3BJun 27, 2026
Humana HUM$137B$1.3BMar 31, 2026

Identity

SEC CIK
59478
LEI
FRDRIPF3EKNDJ2CQJL29
Wikidata
Q632240
SAM UEI
UHHVNTY54K68

Built from SEC EDGAR filings (public domain), the Guidance and KPI Ledgers, Palanor Discourse, U.S. Department of Labor filings, USPTO, USAspending and Senate lobbying records, and rights-checked news headlines. Updated nightly; this page was built Oct 22, 2026. How the Dossier is built

S&P 500, S&P 100, S&P MidCap 400 and Dow Jones Industrial Average are trademarks of S&P Dow Jones Indices LLC or its affiliates; Nasdaq-100 is a trademark of Nasdaq, Inc.; Russell 1000 is a trademark of FTSE Russell. Membership is shown for identification only. Palanor is not affiliated with or endorsed by the index owners.

Cookies

We only use essential cookies to keep you signed in and remember your theme. No analytics, no tracking, no ads. See the Privacy Policy for the full read.